Patents by Inventor Paolo Michieli

Paolo Michieli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-MET antibodies and uses thereof
    Patent number: 12084504
    Abstract: The invention relates to agonistic anti-MET antibodies and uses thereof in the therapeutic treatment of disease. The antibodies bind with high affinity to the human and mouse hepatocyte growth factor (HGF) receptor, also known as MET, and are agonists of MET in both humans and mice, producing molecular and cellular effects resembling the effects of HGF binding.
    Type: Grant
    Filed: August 9, 2021
    Date of Patent: September 10, 2024
    Assignee: AGOMAB THERAPEUTICS
    Inventor: Paolo Michieli
  • ANTI-MET ANTIBODIES AND USES THEREOF
    Publication number: 20240228632
    Abstract: The invention relates to agonistic anti-MET antibodies and uses thereof in the therapeutic treatment of disease. The antibodies bind with high affinity to the human and mouse hepatocyte growth factor (HGF) receptor, also known as MET, and are agonists of MET in both humans and mice, producing molecular and cellular effects resembling the effects of HGF binding.
    Type: Application
    Filed: December 13, 2023
    Publication date: July 11, 2024
    Inventor: Paolo Michieli
  • ANTI-MET ANTIBODIES AND USES THEREOF
    Publication number: 20240132601
    Abstract: The invention relates to agonistic anti-MET antibodies and uses thereof in the therapeutic treatment of disease. The antibodies bind with high affinity to the human and mouse hepatocyte growth factor (HGF) receptor, also known as MET, and are agonists of MET in both humans and mice, producing molecular and cellular effects resembling the effects of HGF binding.
    Type: Application
    Filed: December 13, 2023
    Publication date: April 25, 2024
    Inventor: Paolo Michieli
  • Anti-MET agonist antibody for use in the treatment of colorectal cancer
    Patent number: 11834507
    Abstract: The present invention relates to treatment of cancer using agonist anti-MET antibodies or fragments thereof. In particular, the invention relates to treatment of colorectal cancer using agonist anti-MET antibodies or fragments, typically colorectal cancer associated with chronic inflammation and/or gene mutations in the colon and in the gastrointestinal tract in general. The invention further relates to treating intestinal fibrosis using agonist anti-MET antibodies.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: December 5, 2023
    Assignee: Agomab Therapeutics
    Inventor: Paolo Michieli
  • ANTI-MET ANTIBODIES AND USES THEREOF
    Publication number: 20220153850
    Abstract: The invention relates to agonistic anti-MET antibodies and uses thereof in the therapeutic treatment of disease. The antibodies bind with high affinity to the human and mouse hepatocyte growth factor (HGF) receptor, also known as MET, and are agonists of MET in both humans and mice, producing molecular and cellular effects resembling the effects of HGF binding.
    Type: Application
    Filed: August 9, 2021
    Publication date: May 19, 2022
    Inventor: Paolo Michieli
  • Anti-MET antibodies and uses thereof
    Patent number: 11098126
    Abstract: The invention relates to agonistic anti-MET antibodies and uses thereof in the therapeutic treatment of disease. The antibodies bind with high affinity to the human and mouse hepatocyte growth factor (HGF) receptor, also known as MET, and are agonists of MET in both humans and mice, producing molecular and cellular effects resembling the effects of HGF binding.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: August 24, 2021
    Assignee: AGOMAB THERAPEUTICS BVBA
    Inventor: Paolo Michieli
  • Anti c-Met antibodies
    Patent number: 10676535
    Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: June 9, 2020
    Assignee: argenx BVBA
    Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge, Paolo Michieli, Cristina Basilico, Torsten Dreier
  • Antibody fragments, compositions and uses thereof
    Patent number: 10351628
    Abstract: An isolated nucleic acid encoding a monovalent antibody fragment comprising a first polypeptide comprising a light chain variable domain and two constant domains and a second polypeptide comprising a heavy chain variable domain and two constant domains, wherein two chain constant domains are light chain constant domains and two constant domains are CH1 heavy chain constant domains.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: July 16, 2019
    Assignee: METIS PRECISION MEDICINE SB S.R.L.
    Inventors: Elisa Vigna, Paolo Michieli, Paolo Maria Comoglio
  • Antibody fragments, compositions and uses thereof
    Patent number: 9975952
    Abstract: Antibody fragment comprising a first polypeptide comprising a light chain variable domain and two constant domains and a second polypeptide comprising a heavy chain variable domain and two constant domains, wherein two chain constant domains are light chain constant domains and two constant domains are CHI heavy chain constant domains.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: May 22, 2018
    Assignee: METIS PRECISION MEDICINE SB S.R.L.
    Inventors: Elisa Vigna, Paolo Michieli, Paolo Maria Comoglio
  • Anti c-Met antibodies
    Patent number: 9884917
    Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: February 6, 2018
    Assignee: ARGEN-X N.V.
    Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge, Paolo Michieli, Cristina Basilico, Torsten Dreier
  • C-Met antibody combinations
    Patent number: 9688773
    Abstract: The invention provides a product combination or composition, and also multispecific antibodies comprising two or more antigen-binding sites (as antibodies or antigen binding fragments thereof), wherein two the antigen-binding bind to distinct non-overlapping epitopes of the human c-Met protein. The product combination or composition or multispecific antibody inhibits HGF-independent activation of the human c-Met receptor protein.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: June 27, 2017
    Assignee: ARGEN-X N.V.
    Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge, Paolo Michieli, Cristina Basilico, Torsten Dreier
  • High affinity binding site of HGFR and methods for identification of antagonists thereof
    Patent number: 9310377
    Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: April 12, 2016
    Assignee: METHERESIS TRANSLATIONAL RESEARCH SA
    Inventors: Paolo Maria Comoglio, Paolo Carminati, Paolo Michieli, Cristina Basilico
  • Method for treating cancer or cancer metastasis
    Patent number: 9121854
    Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: September 1, 2015
    Assignee: METHERESIS TRANSLATIONAL RESEARCH S.A.
    Inventors: Cristina Basilico, Paolo Michieli, Paolo Carminati, Paolo Maria Comoglio
  • ANTI C-MET ANTIBODIES
    Publication number: 20140205606
    Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.
    Type: Application
    Filed: December 6, 2013
    Publication date: July 24, 2014
    Applicant: ARGEN-X B.V.
    Inventors: Anna HULTBERG, Michael SAUNDERS, Johannes DE HAARD, Els FESTJENS, Natalie DE JONGE, Paolo Michieli, Christina Basilico, Torsten Dreier
  • Anti c-Met antibodies
    Patent number: 8637027
    Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: January 28, 2014
    Assignee: arGEN-X B.V.
    Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge, Paolo Michieli, Cristina Basilico, Torsten Dreier
  • HIGH AFFINITY BINDING SITE OF HGFR AND METHODS FOR IDENTIFICATION OF ANTAGONISTS THEREOF
    Publication number: 20130183690
    Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.
    Type: Application
    Filed: February 21, 2013
    Publication date: July 18, 2013
    Applicant: Metheresis Translational Research SA
    Inventors: Paolo Maria COMOGLIO, Paolo Carminati, Paolo Michieli, Cristina Basilico
  • High affinity binding site of HGFR and methods for identification of antagonists thereof
    Patent number: 8404453
    Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extracellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: March 26, 2013
    Assignee: Metheresis Translational Research SA
    Inventors: Cristina Basilico, Paolo Michieli, Paolo Carminati, Paolo Maria Comoglio
  • ANTI C-MET ANTIBODIES
    Publication number: 20120148607
    Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.
    Type: Application
    Filed: November 3, 2011
    Publication date: June 14, 2012
    Applicant: ARGEN-X B.V.
    Inventors: Anna HULTBERG, Michael SAUNDERS, Johannes DE HAARD, Els FESTJENS, Natalie DE JONGE, Paolo Michieli, Cristina Basilico, Torsten Dreier
  • High affinity binding site of HGFR and methods for identification of antagonists thereof
    Publication number: 20120115219
    Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.
    Type: Application
    Filed: August 31, 2011
    Publication date: May 10, 2012
    Applicant: Metheresis Translational Research SA
    Inventors: Cristina Basilico, Paolo Michieli, Paolo Carminati, Paolo Maria Comoglio
  • High affinity binding site of HGFR and methods for identification of antagonists thereof
    Publication number: 20120108789
    Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.
    Type: Application
    Filed: August 31, 2011
    Publication date: May 3, 2012
    Applicant: Metheresis Translational Research SA
    Inventors: Cristina Basilico, Paolo Michieli, Paolo Carminati, Paolo Maria Comoglio